A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

  • STATUS
    Recruiting
  • End date
    Sep 15, 2029
  • participants needed
    242
  • sponsor
    RTOG Foundation, Inc.
Updated on 21 June 2021
Investigator
Edwin Posadas, MD
Primary Contact
McLaren Cancer Institute - Port Huron (1.4 mi away) Contact
+103 other location
platelet count
prostatectomy
gonadotropin
androgens
growth factor
testosterone
antiandrogen therapy
androgen suppression
bicalutamide
prostate specific antigen
antiandrogens
luteinizing hormone-releasing hormone agonist
enzalutamide
serum testosterone
recurrent prostate cancer
adenocarcinoma
gonadorelin

Summary

Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free survival when enhanced ADT is used compared to standard ADT.

Description

PRIMARY OBJECTIVE:

To determine whether, in men with post-prostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog -based ADT.

Details
Condition Malignant neoplasm of prostate, Prostatic disorder, Prostate Disorders, Prostate Cancer, Early, Recurrent, Prostate Cancer, prostate carcinoma, prostate cancers
Treatment bicalutamide, radiation therapy, Enzalutamide, GnRH analog
Clinical Study IdentifierNCT03809000
SponsorRTOG Foundation, Inc.
Last Modified on21 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Pathologically (histologically) proven adenocarcinoma confirmed by prostatectomy performed within 10 years prior to registration and any type of radical prostatectomy is permitted, including retropubic, perineal, laparoscopic or robotically assisted
PSA level ( 0.2 ng/mL) within 90 days prior to registration. GnRH analog may be started no more than 42 days prior study entry, but patients must have a PSA 0.2 ng/mL prior to starting ADT
Hemoglobin 9.0 g/dL, independent of transfusion and/or growth factors within 90 days prior to registration
Platelet count 75,000 x 10^9/L independent of transfusion and/or growth factors within 90 days prior to registration
At least 1 of the following aggressive features
Gleason score of 8-10 (note any Gleason score is eligible)
Seminal vesicle invasion (SVI) (note any pT stage [AJCC v8.0] is eligible but a pT stage
pT3b is considered aggressive)
Locoregional node involvement at radical prostatectomy (pN1)
Persistently elevated PSA post-RP nadir (PEPP) defined as PSA > 0.1 ng/mL after radical prostatectomy
Serum albumin 3.0 g/dL within 90 days prior to registration
GFR 35 mL/min estimated by Cockcroft-Gault or measured directly by 24 hour urine creatinine within 90 days prior to registration
Serum total bilirubin 1.5 ULN (Note: In subjects with Gilbert's syndrome, if total bilirubin is >1.5 ULN, measure direct and indirect bilirubin and if direct bilirubin is 1.5 ULN, subject is eligible) within 90 days prior to registration
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <2.5 ULN within 90 days prior to registration
Testosterone >50 ng/dL within 90 days prior to registration. Prior androgen deprivation (GnRH analog and/or non-steroidal antiandrogen) therapy is allowed provided that serum testosterone concentration must be 50 ng/dL prior to registration or starting ADT, whichever occurs first; 5-alpha reductase inhibitors will not impact eligibility, but must be discontinued prior to starting protocol treatment
History and physical with ECOG Performance Status 0-1 or within 90 days prior to registration

Exclusion Criteria

Definitive clinical or radiologic evidence of metastatic disease with the exception of locoregional lymph nodes
Prior invasive malignancy (except non-melanomatous skin cancer carcinoma in situ of the male breast, penis, oral cavity, or stage Ta of the bladder, or stage I completely resected melanoma) unless disease free for a minimum of 2 years)
Prior systemic chemotherapy for the study cancer. Note: prior chemotherapy for a different cancer is allowable
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
History of any of the following
Documented inflammatory bowel disease
Transmural myocardial infarction within the last 4 months prior to registration
Unstable angina and/or congestive heart failure requiring hospitalization within the last 4 months prior to registration
New York Heart Association Functional Classification III/IV within 4 months prior to registration
History of loss of consciousness or transient ischemic attack within 12 months prior to randomization
Known gastrointestinal disorder affecting absorption of oral medications
History of seizure disorder or condition that may predispose to seizure (e.g. prior cortical stroke or significant brain trauma)
Active uncontrolled infection defined as an identified infectious condition that requires active therapy that has not yet been completed
History of uncontrolled hypertension defined as a sustained systolic blood pressure in excess of 150 mmHg or a sustained diastolic blood pressure in excess of 90 mmHg despite optimized antihypertensive therapy
HIV positive patients with CD4 count < 200 cells/microliter within 30 days prior to registration OR HIV patients under treatment with highly active antiretroviral therapy (HAART) within 30 days prior to registration regardless of CD4 count. Note: HIV testing is not required for eligibility for this protocol as it is self-reported. This exclusion criterion is necessary because the treatments involved in this protocol may be immunosuppressive and/or interact with HAART
History of repeated falls and fractures over the past 12 months that in the opinion of the treating investigator would put the patient at risk for poor bone outcomes from androgen receptor targeted therapy
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note